Silverfleet invests in Aesica Pharmaceuticals

The capital will be used to expand into new markets and further grow the company.

Members of Aesica's executive board have acquired a large minority stake.

Debt
A debt structure was provided by Lloyds, HSBC and Yorkshire Bank.

Previous funding
LDC acquired Aesica in August 2004 for £40m from BASF. Lloyds TSB Bank provided a mezzanine facility for the deal.

Company
Aesica is a developer and manufacturer of primary and secondary stage pharmaceuticals, operating facilities in the UK, Germany and Italy. Headquartered in Newcastle, the firm generates a turnover of €180m.

People
David Mackenzie and Adrian Yurkwich will join the board as non-executive directors. Both worked on the buyout together with Joachim Braun for Silverfleet Capital.

Advisers
Equity - Travers Smith (Legal); PwC (Financial due diligence);
Company - PwC (Corporate finance); Ward Hadaway (Legal)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Buyouts
• Healthcare
• Duke Street